Story Feb. 6 - X4 Pharmaceuticals ... Story Feb. 5 - Viracta Therapeutics: The cancer biotech has closed its doors, laying off all employees and winding down operations. Story Feb. 5 - Frontier ...

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “sell (d-)” rating reiterated by stock analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Padmanabh ...

Aquestive Therapeutics Inc (NASDAQ:AQST) has begun the FDA filing process for its Afilm epinephrine sublingual film, with expectations for NDA acceptance by June 2025. The company is on track to ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery ...

March 10 (Reuters) - India's Sun Pharmaceutical Industries (SUN.NS), opens new tab said on Monday it will acquire Checkpoint Therapeutics (CKPT.O), opens new tab, a U.S.-based immunotherapy and ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...

Janux Therapeutics has a twelve month low of $29.63 and a twelve month high of $71.71. The stock has a fifty day simple moving average of $41.27 and a 200 day simple moving average of $47.48.

Arcturus Therapeutics Holdings Inc. (ARCT) reported a wider-than-expected loss for the fourth quarter of 2024, with earnings per share (EPS) of -$1.11, missing the forecast of -$0.19. The company ...

Good day, everyone, and welcome to today's Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later ...